131-I-METAIODOBENZYLGUANIDINE (131I-MIBG) THERAPY FOR REFRACTORY NEUROBLASTOMA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neuroblastomas are one of the most common solid tumors of childhood. Despite modern advances in chemotherapy and radiation therapy, the ability to cure most patients with neuroblastoma is currently < 30%. Patients who fail to respond to initial chemotherapy (called induction therapy), or those patients whose tumors relapse have even a much lower chance for cure. The cure rate for such patients is < 10%. The purpose of this protocol is to treat those patients with the greatest chance of dying from their cancer- those patients with relapsed neuroblastoma or those patients who fail induction therapy. The patients will be treated with a radio-active chemical that is called 131-I MIBG. The hope is that the MIBG will deliver radiation specifically to the tumor, thereby sparing the rest of the body the effects of the radiation.